

# DF/HCC Breast and Gynecologic Cancer Symposium

March 28, 2025 | 7:45 AM – 3:00 PM

Joseph B. Martin Conference Center | 77 Avenue Louis Pasteur, Boston, MA

7:45 AM	<b>Sign-In, Continental Breakfast, Poster Set-Up</b>
8:30 AM	<b>Welcome/Purpose of Symposium   Susan F. Smith Center Leaders</b>
	<b>J. Dirk Iglehart, M.D., Visiting Scholar Lecture</b> <b>Translational Cancer Research: Data is the Answer and the Question</b> <i>(35-40 min talk, 10 mins questions)</i>
8:40 AM	<b>Daniel G. Stover, MD, FASCO</b> Associate Professor of Internal Medicine & Biomedical Informatics Division of Medical Oncology Director, Translational Breast Cancer Research Ohio State University Comprehensive Cancer Center James Cancer Hospital & Solove Research Institute
	<b>SESSION I: Genomics</b> <b>Chair:</b> Gerburg Wulf, MD, PhD <i>3 oral presentations (10 mins each; 5 mins questions)</i>
9:30 - 10:15 AM	<b>Dominik Glodzik, PhD:</b> Mutational signatures reveal the age of onset of homologous recombination deficiency before cancer diagnosis <b>Kavya Prasad, MPH:</b> The Unique Clonal Genomic Evolution of Invasive Lobular Breast Cancer During Neoadjuvant Endocrine Therapy <b>Ignacio Vazquez-Garcia, PhD:</b> Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer
10:15 AM	<b>Coffee Break (15 min)</b>
	<b>SESSION II: Risk, Prevention &amp; Disparities/Clinical</b> <b>Chair:</b> Sara Tolaney, MD, MPH <i>3 oral presentations (10 mins each; 5 mins questions)</i>
10:30 - 11:15 AM	<b>Kathy Situ, PhD Candidate:</b> BRCA2- Deficiency Induced APOBEC3 Drives Genomic Instability upon Replication Stress <b>Kyle Anderman, BS:</b> Long-term safety of prophylactic and therapeutic nipple-sparing mastectomies in BRCA1 and BRCA2 mutation carriers <b>Guilherme Nader Marta, MD:</b> Impact of Pregnancy History and Recency of Childbirth on Long-Term Outcomes in Young Patients with Early-Stage Breast Cancer

## AGENDA CONT'D

11:15 AM	<p><b>M. Patricia Cronin Memorial Lecture</b> <b>Antibody Drug Conjugates in Gynecologic Cancers: Using Science, Sequency, and Strategy to Optimize Outcomes</b> <i>(35-40 min talk, 10 mins questions)</i></p> <p><b>Kathleen N. Moore, MD, MS, FASCO</b> Deputy Director Co-Director Cancer Therapeutics Program Stephenson Cancer Center at OU Health Professor, Gynecologic Oncology University of Oklahoma, HSC</p>
12:05 PM	<b>Lunch and Open Posters</b>
1:15 - 2:00 PM	<p><b>SESSION III: Drug Resistance/Animal Models</b> <b>Chair:</b> Patricia Donahoe, MD <i>3 oral presentations (10 mins each; 5 mins questions)</i></p> <p><b>Xin Cheng, PhD:</b> FGFR Inhibition Overcomes Therapeutic Resistance and Immune Evasion in Oncogenic PIK3CA-Driven Serous Endometrial Cancers <b>Jie Hao, MD, PhD:</b> PTEN deficiency as a predictive biomarker for response to ATR inhibition as monotherapy and in combination with PARP inhibition in BRCA-mutant ovarian cancer <b>Zuen Ren, MD, PhD:</b> SIRT5 promotes chemoresistance through metabolic rewiring for nucleotide replenishing in refractory triple-negative breast cancer</p>
2:00 - 2:45 PM	<p><b>SESSION IV: Tumor Microenvironment/Immunology</b> <b>Chair:</b> Panagiotis Konstantinopoulos, MD, PhD <i>3 oral presentations (10 mins each; 5 mins questions)</i></p> <p><b>Maclean Sellars, MD, PhD:</b> Ovarian NeoVax: Neoantigen vaccination applies immune pressure in a checkpoint recalcitrant disease <b>Jun Nishida, PhD:</b> Spatial proteomic analysis uncovered epigenetic vulnerabilities and heterogeneity of triple-negative breast cancer brain metastases <b>Ozge Somuncu, PhD:</b> Replication stress as a driver of breast tumorigenesis in BRCA1 heterozygous carrier-derived breast organoids</p>
2:45 PM	<b>Announcement of Awards and Adjourn</b>